Form 4 for ADIL ADIAL PHARMACEUTICALS, INC.
Accepted 2022-02-25 00:00:00 ET · period of report 2022-02-23 · accession 0001213900-22-009432 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-25 | 2022-02-23 | ADIL | Stilley William B. III | CEO, Dir | A - Grant | $0.00 | +250.0K | 1.19M | +27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-23 | A | A | 250,000 | $0.00 | 1,187,646 | D | — | — | (F1) The restricted shares of Adial Pharmaceuticals, Inc. (the "Company") common stock, par value $0.001 per share (the "Common Stock"), vest as to 166,667 shares monthly on a pro rata basis over 24 months commencing March 23, 2022 and vest as to 83,333 shares on the three year anniversary of the grant date. |